Evaluation of Fractional Bipolar Radiofrequency for the Treatment of Striae

Sponsor
Candela France (Industry)
Overall Status
Completed
CT.gov ID
NCT01788748
Collaborator
(none)
22
2
3
9
11
1.2

Study Details

Study Description

Brief Summary

This is an interventional open prospective randomized study, done in two sites.

The main purpose of this study is to evaluate the efficacy of the combination of bipolar radiofrequency potentiated by an infrared light followed by fractional bipolar radiofrequency for the treatment of striae on the abdomen.

In order to have a more complete and accurate study, each technology will also be evaluated separately. This will allow the comparison of the effect of each treatment, in monotherapy or combined.

Condition or Disease Intervention/Treatment Phase
  • Device: bipolar radiofrequency and infrared
  • Device: fractional bipolar radiofrequency
N/A

Detailed Description

Stria is a very common condition that affects psychologically and aesthetically a lot of patients. It is a linear atrophic scar. So, to be treated, it needs to have both a superficial and a deep impact.

Several technologies have already been tested for this indication, but none of them have been proved at the same time effective and without a high risk of side effects for all skin types. As radiofrequency is an electrical current, it is not absorbed and does not see melanin. So it can be used on all skin types.

When using fractional bipolar radiofrequency, the current goes from small electrodes to return electrodes. Around the small electrodes appear some epidermal ablation, coagulation and deeper thermal damage. This means it has a superficial and a deep effect.

Using infrared combined with bipolar radiofrequency allows the infrared to pre-heat the skin so as to help the radiofrequency to go deeper in the skin more easily. This has a deep effect in the dermis.

In this study, both technologies will be used. At least 20 patients will be treated in two different sites.

The abdomen of each patient will be divided in four quadrants around the navel. Each quadrant will receive a total of three treatments one month apart:

  • One quadrant will be the control (no treatment will be done)

  • One quadrant will receive each time only bipolar radiofrequency potentiated by infrared

  • One quadrant will receive each time only fractional bipolar radiofrequency

  • One quadrant will receive each time first bipolar radiofrequency potentiated by infrared, followed in the same session by fractional bipolar radiofrequency.

The choice of the treatment for each area will be randomized at the enrollment of the patient in the study.

There will be two follow-up sessions 3 and 6 months after the last treatment.

The evaluation will be done mainly by 3D acquisitions. This will allow measuring the length, width and depth of the striae and evaluating their evolution after the treatment.

Some patients, if they agree, will also have in vivo confocal microscopy before the first treatment and 6 months after the last one. This will give more information on the collagen and elastin changes.

Four patients, who accept it, will have biopsies performed before the first treatment and 6 months after the last one to also show the evolution of the skin structure.

Study Design

Study Type:
Interventional
Actual Enrollment :
22 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluation of Fractional Bipolar Radiofrequency, and Bipolar Radiofrequency Potentiated by Infrared, in Monotherapy or Combined, for the Treatment of Striae
Study Start Date :
Feb 1, 2013
Actual Primary Completion Date :
Nov 1, 2013
Actual Study Completion Date :
Nov 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: bipolar radiofrequency and infrared

The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive only bipolar radiofrequency potentiated by infrared, 3 treatments one month apart.

Device: bipolar radiofrequency and infrared
Other Names:
  • Applicator Sublime on the platform eTwo
  • Active Comparator: fractional bipolar radiofrequency

    The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive only fractional bipolar radiofrequency , 3 treatments one month apart.

    Device: fractional bipolar radiofrequency
    Other Names:
  • applicator Sublative, platform eTwo
  • Active Comparator: combined treatment

    The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive first bipolar radiofrequency potentiated by infrared, followed in the same session by fractional bipolar radiofrequency, 3 treatments one month apart.

    Device: bipolar radiofrequency and infrared
    Other Names:
  • Applicator Sublime on the platform eTwo
  • Device: fractional bipolar radiofrequency
    Other Names:
  • applicator Sublative, platform eTwo
  • Outcome Measures

    Primary Outcome Measures

    1. Change of striae volume [before the first treatment, 3 and 6 months after the last treatment. Months 0, 5 and 8]

      The stretch marks in each area will be evaluated with a 3D camera (Antera 3D, Miravex). This will give access to the length, width and depth of each stria. Those measurements will then be compared so as to evaluate each technology.

    Secondary Outcome Measures

    1. Observation of the skin structure changes with in vivo confocal microscopy [5 months]

      In vivo confocal microscopy acquisitions will be done on all subjects who agree to do so. It is a non-invasive imaging procedure that shows the different structures of the skin (such as collagen fibers and elastin). This will allow us to assess the effect of both technologies, used in monotherapy or combined, on those structures.

    2. Observation of the skin structure changes with in vivo confocal microscopy [8 months]

      In vivo confocal microscopy acquisitions will be done on all subjects who agree to do so. It is a non-invasive imaging procedure that shows the different structures of the skin (such as collagen fibers and elastin). This will allow us to assess the effect of both technologies, used in monotherapy or combined, on those structures.

    3. Observation of the skin structure changes by histology [8 months]

      For four patients, who previously agreed to do so, 3 biopsies will be done (one on each quadrant that will receive a treatment) before any treatment and at the 6 month follow-up session. They will be analyzed in the anatomopathology laboratory of the Archet II hospital. It will show the entire dermal and epidermal evolution after each type of treatment.

    4. Pain assessment [1 month]

      Pain will be assessed with an analogical visual scale.

    5. Pain assessment [2 months]

      Pain will be assessed with an analogical visual scale.

    6. Global satisfaction [1 month]

      The global satisfaction of both the subject and the investigator will be assessed with an analogical visual scale.

    7. Global satisfaction [2 months]

      The global satisfaction of both the subject and the investigator will be assessed with an analogical visual scale.

    8. Double blinded pictures observation [5 months]

      Standardized pictures will be taken at the beginning of each session. Two external doctors will evaluate each picture on a Physician Global Assessment scale, without knowing to which session or to which subject it corresponds.

    9. Double blinded pictures observation [8 months]

      Standardized pictures will be taken at the beginning of each session. Two external doctors will evaluate each picture on a Physician Global Assessment scale, without knowing to which session or to which subject it corresponds.

    10. global satisfaction [5 months]

      The global satisfaction of both the subject and the investigator will be assessed with an analogical visual scale.

    11. Global satisfaction [8 months]

      The global satisfaction of both the subject and the investigator will be assessed with an analogical visual scale.

    12. Pain assessment [first day]

      Pain will be assessed with an analogical visual scale.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Male and female subject over 18 years old, with striae on all the abdomen (white or red)

    • Consent form signed by subjects

    • Affiliation to social security

    Exclusion Criteria:
    • Electrical implants (pace maker, defibrillator) or superficial metallic implants (gold thread…)

    • Pregnant woman

    • Woman who can procreate without using an effective birth control

    • Deficient immune system due to immunosuppressive diseases such as AIDS or HIV, or use of immunosuppressive drugs,

    • Stretch marks resulting from treatment with steroids,

    • Treatment with oral retinoids ongoing or stopped less than a year ago, or photosensitizing ongoing or stopped less than 3 months ago

    • History of diseases stimulated by heat (recurrent herpes) on the treatment area

    • Procedure less than 6 months ago performed on the treatment area,

    • History of keloid scarring or difficulty in healing,

    • History of allergy to xylocaine (for subjects who will have biopsy)

    • Dermatological disorder requiring systemic therapy or local therapy in the area under study,

    • Systemic disease in evolution (cancer or history of cancer, heart disease, uncontrolled diabetes, pain syndrome, history of neuropathy)

    • Problem of coagulation and / or anticoagulant therapy,

    • Vascular lesions or tattoos on the treatment area,

    • Vulnerable Person: minor, under protection, deprived of liberty.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Aesthetics Bordeaux France 33200
    2 CHU Archet II, Service de Dermatologie Nice France 06200

    Sponsors and Collaborators

    • Candela France

    Investigators

    • Principal Investigator: Thierry Passeron, Pr, Hopital Archet II, service de Dermatologie

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Candela France
    ClinicalTrials.gov Identifier:
    NCT01788748
    Other Study ID Numbers:
    • PRB-E2VER02
    • 2012-A01427-36
    • 12.084
    First Posted:
    Feb 11, 2013
    Last Update Posted:
    Dec 31, 2013
    Last Verified:
    Dec 1, 2013
    Keywords provided by Candela France
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 31, 2013